Medicare Part D's effect on the under- and overuse of medications: A systematic review

Journal of the American Geriatrics Society

Volumn 59, Issue 10, 2011, Pages 1922-1933

  Polinski, Jennifer M ^a,b   Donohue, Julie M ^c   Kilabuk, Elaine ^d   Shrank, William H ^a,b,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

Medicare Part D; medication overuse; medication underuse; systematic review

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DEXTROPROPOXYPHENE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PROTON PUMP INHIBITOR; SEDATIVE AGENT; SPASMOLYTIC AGENT; UNINDEXED DRUG; WARFARIN;

ANTIBIOTIC THERAPY; ARTICLE; DRUG USE; HEALTH INSURANCE; HUMAN; MEDICAL LITERATURE; MEDICARE; PEER REVIEW; PHARMACEUTICAL CARE; RESPIRATORY TRACT INFECTION; SYSTEMATIC REVIEW;

AGED; AGED, 80 AND OVER; CHRONIC DISEASE; COMORBIDITY; COST SHARING; DRUG COSTS; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; LONG-TERM CARE; MALE; MEDICARE PART D; UNITED STATES;

EID: 80054810978     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2011.03537.x     Document Type: Article

References (50)

1. Centers for Medicare and Medicaid Services. Medicare Program; Medicare Prescription Drug Benefit; Final Rule, 42 CFR 70, no. 18, 4460 Federal Register. 2005.
2. Pauly MV., Medicare drug coverage and moral hazard. Health Aff 2004; 23: 113-122.
3. Keeler EB, Buchanan JL, Rolph JE, et al,. The Demand for Episodes of Medical Treatment in the Health Insurance Experiment. Santa Monica, CA: RAND Corp., 1988.
4. Federman AD, Adams AS, Ross-Degnan D, et al,. Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease. JAMA 2001; 286: 1732-1739.
5. Tamblyn R., The impact of pharmacotherapy policy: A case study. Can J Clin Pharmacol 2001; 8 (Suppl A): 39A-44A.
6. Shrank WH, Asch SM, Joseph GJ, et al,. Physicians' perceived knowledge of and responsibility for managing patients' out-of-pocket costs for prescription drugs. Ann Pharmacother 2006; 40: 1534-1540.
7. Shrank WH, Joseph GJ, Choudhry NK, et al,. Physicians' perceptions of relevant prescription drug costs: Do costs to the individual patient or to the population matter most? Am J Manag Care 2006; 12: 545-551.
8. Huskamp HA, Stevenson DG, Donohue JM, et al,. Coverage and prior authorization of psychotropic drugs under Medicare Part D. Psych Serv 2007; 58: 308-310.
9. Breisacher BA, Soumerai SB, Field TS, et al,. Medicare Part D's exclusion of benzodiazepines and fracture risk in nursing homes. Arch Intern Med 2010; 170: 693-698.
10. Wells G, Shea B, O'Connell D, et al,. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Paper presented at: Proceedings of the 3rd Symposium on Systematic Reviews. Beyond the basics: Improving quality and impact, 2000, Oxford.
11. Pfisterer M, Buser P, Rickli H, et al,. BNP-guided vs symptom-guided heart failure therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009; 301: 383-392.
12. Lewis WR, Ellrodt AG, Peterson E, et al,. Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: Findings from the get with the guidelines quality-improvement program. Circ Cardio Qual Outcomes 2009; 2: 633-641.
13. Bonde L, Sorensen R, Fosbol EL, et al,. Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: A nationwide study. J Am Coll Cardiol 2010; 55: 1300-1307.
14. Lee TJ, Fennerty MB, Howden CW., Systematic review: Is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2004; 20: 1241-1251.
15. Gill SS, Bronskill SE, Normand SL, et al,. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146: 775-786.
16. Gupta R, Garg P, Kottoor R, et al,. Overuse of acid suppression therapy in hospitalized patients. South Med J 2010; 103: 207-211.
17. Hanlon JT, Schmader KE, Boult C, et al,. Use of inappropriate prescription drugs by older people. J Am Geriatr Soc 2002; 50: 26-34.
18. Shrank WH, Polinski JM, Avorn J., Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc 2007; 55 (Suppl 2): S373-S382.
19. American Psychiatric Association. Practice guideline: Treatment of Patients With Alzheimer's Disease and Other Dementias [on-line]. Available at Accessed December 9, 2008.
20. Schneider LS, Tariot PN, Dagerman KS, et al,. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355: 1525-1538.
21. Jureidini J, Tonkin A., Overuse of antidepressant drugs for the treatment of depression. CNS Drugs 2006; 20: 623-632.
22. Gonzales R, Steiner JF, Sande MA., Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997; 278: 901-904.
23. Chen H, Nwangwu A, Aparasu R, et al,. The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psych Serv 2008; 59: 1191-1197.
24. Domino ME, Farley JF., Did Medicare Part D improve access to medications? Psych Serv 2010; 62: 118-120.
25. Donohue JM, Huskamp HA, Zuvekas SH., Dual eligibles with mental disorders and Medicare part D: How are they faring? Health Aff 2009; 28: 746-759.
26. Donohue JM, Marcum ZA, Zhang Y, et al,. Medicare Part D's Impact on the Use of High Risk Medications Among Older Adults. Boston, MA: Academy Health, 2010.
27. Donohue JM, Zhang Y, Lave JR, et al,. The Medicare drug benefit (Part D) and treatment of heart failure in older adults. Am Heart J 2010; 160: 159-165.
28. Donohue JM, Zhang Y, Men A, et al,. Impact of Medicare Part D on antidepressant treatment, medication choice and adherence among older adults with depression. Am J Geriatr Psychiatr 2011, in press.
29. Fu AZ, Tang AS, Wang N, et al,. Effect of Medicare Part D on potentially inappropriate medication use by older adults. J Am Geriatr Soc 2010; 58: 944-949.
30. Zhang Y, Donohue JM, Lave JR, et al,. The impact of Medicare Part D on medication treatment of hypertension. Health Serv Res 2011; 46: 185-198.
31. Zhang Y, Donohue JM, Lave JR, et al,. The effect of Medicare Part D on drug and medical spending. N Engl J Med 2009; 363: 52-61.
32. Zhang Y, Lave JR, Donohue JM, et al,. The impact of Medicare Part D on medication adherence among older adults enrolled in Medicare-Advantage products. Med Care 2010; 48: 409-417.
33. Zhang Y, Lee BY, Donohue JM., Ambulatory antibiotic use and prescription drug coverage in older adults. Arch Intern Med 2010; 170: 1308-1314.
34. Das-Douglas M, Riley ED, Ragland K, et al,. Implementation of the Medicare Part D prescription drug benefit is associated with antiretroviral therapy interruptions. AIDS Behav 2009; 13: 1-9.
35. Shrank WH, Patrick AR, Pedan A, et al,. The effect of transitioning to Medicare Part D Drug coverage in seniors dually eligible for Medicare and Medicaid. J Am Geriatr Soc 2008; 56: 2304-2310.
36. West JC, Wilk JE, Muszynski IL, et al,. Medication access and continuity: The experiences of dual-eligible psychiatric patients during the first 4 months of the Medicare prescription drug benefit. Am J Psychiatr 2007; 164: 789-796.
37. Golden A, Roos BA, Beers MH., The unintended outcome of a supplemental formulary in homebound seniors. J Am Geriatr Soc 2009; 57: 927-929.
38. West JC, Wilk JE, Rae DS, et al,. First-year Medicare Part D prescription drug benefits: Medication access and continuity among dual eligible psychiatric patients. J Clin Psychiatr 2010; 71: 400-410.
39. Raebel MA, Delate T, Ellis JL, et al,. Effects of reaching the drug benefit threshold on Medicare members' healthcare utilization during the first year of Medicare Part D. Med Care 2008; 46: 1116-1122.
40. Schneeweiss S, Patrick AR, Pedan A, et al,. The effect of Medicare Part D drug coverage on drug use and cost-sharing in seniors without prior drug benefits. Health Aff 2009; 28: 305-316.
41. Hargrave E, Hoadley J, Summer L, et al,. Medicare Part D 2010 Data Spotlight: Benefit Design and Cost-Sharing. Menlo Park, CA: Kaiser Family Foundation, 2010.
42. Goldman DP, Joyce GF, Zheng Y., Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. JAMA 2007; 298: 61-69.
43. Tamblyn R, Laprise R, Hanley JA, et al,. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001; 285: 421-429.
44. Shrank WH, Hoang T, Ettner SL, et al,. The implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 2006; 166: 332-337.
45. Schneeweiss S, Walker AM, Glynn RJ, et al,. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med 2002; 346: 822-829.
46. Chernew ME, Shah MR, Wegh A, et al,. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff 2008; 27: 103-112.
47. Choudhry NK, Fischer MA, Avorn J, et al,. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff 2010; 29: 1995-2001.
48. Cubanski J, Neuman P., Status report on Medicare Part D enrollment in 2006: Analysis of plan-specific market share and coverage. Health Aff 2007; 26: w1-w12.
49. Patient Protection and Affordable Care Act. P.L. No. 111-148, 11th Congress, 2nd session, 2010.
50. Congressional Budget Office. Cost estimate for the amendment in the nature of a substitute for H.R. 4872, incorporating a proposed manager's amendment made public on March 20, 2010 [on-line]. Available at Accessed October 22, 2010.